NCT01568463

Brief Summary

Patients experience significant postoperative pain following shoulder surgery, Single shot interscalene block is used in ambulatory shoulder surgery for its advantages that include significant reduction in acute pain and analgesic requirements, prolonged time to first analgesic request, decreased incidence of nausea, as well as earlier hospital discharge.The process of nerve block requires several needle passes, with each of them being at risk of causing nerve injury either by direct trauma or intraneural injection even with the use of the ultrasound. These facts raised concerns and several authors stated that maybe the anesthesiologists should be more careful, keep a safe distance from the nerve, and inject the local anesthetics into fascial planes containing the nerve and not attempt to place the needle in close proximity to the nerve. This study is designed to determine the maximal effective distance away from the nerve for the injection to be effective.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
25

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Feb 2012

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2012

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

March 6, 2012

Completed
27 days until next milestone

First Posted

Study publicly available on registry

April 2, 2012

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 24, 2013

Completed
1.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

March 26, 2014

Completed
Last Updated

January 10, 2018

Status Verified

January 1, 2018

Enrollment Period

12 months

First QC Date

March 6, 2012

Last Update Submit

January 8, 2018

Conditions

Keywords

Inter-scalene BlockRegional Anesthesiashoulder surgeries

Outcome Measures

Primary Outcomes (1)

  • Success of the inter-scalene block at 20 minutes after injection at a specific distance of the needle tip from the outer sheeth of the nerve

    20 mins

Secondary Outcomes (7)

  • The onset time of sensory and motor block

    the block success will be assessed for each patient every 5 min for 20 mins in the block room beginning when the needle exits the skin

  • The proportion of inadequate and failed blocks.

    the block success will be assessed for each patient every 5 min for 20 mins in the block room beginning when the needle exits the skin

  • The duration of block, defined as the time from the completion of block performance to the time of the request for the first postoperative analgesic.

    during the first 24 hours post operative

  • The amount of pain and level of satisfaction,

    every 30 minutes starting at post anesthesia care unit admission till 120 minutes

  • The presence of a Claude-Bernard-Horner Syndrome

    up to 24 hours post operative

  • +2 more secondary outcomes

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients undergoing shoulder surgery (shoulder arthroscopy or open shoulder surgery)

You may qualify if:

  • ASA physical status I-III
  • years of age, inclusive
  • surgery less than 3 hours

You may not qualify if:

  • contraindications to brachial plexus block (e.g., allergy to local anesthetics, coagulopathy, malignancy or infection in the area)
  • existing neurological deficit in the area to be blocked
  • pregnancy
  • history of neck surgery or radiotherapy
  • severe respiratory disease
  • inability to understand the informed consent and demands of the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Toronto Western Hospital

Toronto, Ontario, M5T 2S8, Canada

Location

Study Officials

  • Richard Brull, MD, FRCPC

    University of Toronto

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 6, 2012

First Posted

April 2, 2012

Study Start

February 1, 2012

Primary Completion

January 24, 2013

Study Completion

March 26, 2014

Last Updated

January 10, 2018

Record last verified: 2018-01

Locations